Characteristics and Outcomes of Elderly Patients With Primary Central Nervous System Lymphoma
|
|
- Bernard Potter
- 6 years ago
- Views:
Transcription
1 Characteristics and Outcomes of Elderly Patients With Primary Central Nervous System Lymphoma The Memorial Sloan-Kettering Cancer Center Experience Douglas E. Ney, MD 1 ; Anne S. Reiner, MPH 2 ; Katherine S. Panageas, DrPH 2 ; Hayley S. Brown, BA 1 ; Lisa M. DeAngelis, MD 1 ; and Lauren E. Abrey, MD 1 BACKGROUND: Approximately 50% of all patients with primary central nervous system lymphoma (PCNSL) are aged 65 years; however, this group is relatively understudied, and to the authors s knowledge, optimal treatment for older patients is not well defined. METHODS: This was a retrospective review of PCNSL patients aged 65 years who were treated at Memorial Sloan-Kettering Cancer Center between 1986 and A multivariate analysis of demographic and clinical variables on prognosis and receipt of treatment was performed. RESULTS: One hundred seventy-four patients between the ages of 65 and 89 years were identified; there was a slight predominance of women (52.9%). One hundred forty-eight patients were treated with chemotherapy at the time of diagnosis (98% with methotrexatebased therapy) and 31 of these patients also received whole-brain radiotherapy (WBRT). Sixteen patients received WBRT alone. A radiographic response to chemotherapy was noted in 76% of patients. Ninety patients developed disease progression after initial treatment; 74 received salvage therapy and 48% of these patients responded to salvage treatment. The median overall survival was 25 months (range, months), and the 3-year survival rate was 36%. Approximately 20.1% of patients were alive for 11 years. WBRT was delivered more frequently before 1998, and patients with a history of prior malignancy were less likely to receive WBRT. Age and performance status were identified as the most important predictors of survival. Treatment-related neurotoxicity at 2 years was strongly associated with receipt of WBRT (P ¼.0002). CONCLUSIONS: PCNSL in the elderly remains sensitive to methotrexate-based chemotherapy and aggressive treatment may be warranted both at the time of diagnosis and disease recurrence. Cancer 2010;116: VC 2010 American Cancer Society. KEYWORDS: primary central nervous system lymphoma, elderly, chemotherapy, radiation. Primary central nervous system lymphoma (PCNSL) is a rare form of extranodal non-hodgkin lymphoma (NHL) confined to the brain, cerebrospinal fluid (CSF), spinal cord, leptomeninges, or eyes. PCNSL accounts for <5% of NHLs and approximately 3% of all primary brain tumors. 1 Although rare, the age-adjusted incidence in the United States has increased substantially over the past several decades. 2 Much of this increase was attributed initially to younger patients with human immunodeficiency virus/acquired immune deficiency syndrome; however, the incidence in this specific population has been decreasing due to the development of active antiretroviral drugs. 3 Despite this, the incidence remains high among immunocompetent older patients. 4 Moreover, patients aged >60 years account for approximately half of all those diagnosed with PCNSL, making the elderly a priority in the development of improved therapeutic strategies. In untreated patients the prognosis is poor, with a median survival of 3 to 4 months. 5 Whole-brain radiotherapy (WBRT) alone usually results in a median survival of approximately 12 months, and in patients aged >60 years, the median is only 7.6 months. 6 Multiple prospective studies using chemotherapy in combination with WBRT have shown improved median survivals of 30 to 60 months However, prolonged survival was accompanied by a high rate of Corresponding author: Lisa M. DeAngelis, MD, Department of Neurology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065; Fax: (212) ; deangell@mskcc.org Douglas E. Ney s current address: University of Colorado Denver Health Sciences Center, Aurora, Colorado 1 Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, New York; 2 Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, New York DOI: /cncr.25363, Received: January 8, 2010; Revised: February 24, 2010; Accepted: March 2, 2010, Published online June 22, 2010 in Wiley Online Library (wileyonlinelibrary.com) Cancer October 1,
2 neurotoxicity, particularly in the elderly. 16 Recent trials have suggested that older patients treated with methotrexate-based chemotherapy and deferred WBRT can achieve high response rates and comparable survival without neurotoxicity, but a shorter progression-free survival. 8,14,17,18 Despite these advances, prognosis remains worse in the elderly than in younger patients, even when the same treatment regimen is used in both populations. Age and performance status have been identified as the 2 most important prognostic factors, with age 50 years conveying a worse prognosis. 19 Ageisthestrongestprognosticfactor, and in some series exerts a stronger effect on survival than treatment regimen. 20 In addition, therapeutic advances have not been translated into widespread community practice, particularly among older patients. In a prior study using data from the Surveillance, Epidemiology, and End Results (SEER) cancer registry linked with Medicare claims, we found that only 80% of patients aged 65 years with newly diagnosed PCNSL received any treatment. 21 Only 43% of treated patients received any chemotherapy, whereas 36% received WBRT alone. Furthermore, advancing age was associated with less therapy and increasing use of WBRT alone, a suboptimal therapeutic approach. 18 Balancing treatment efficacy with toxicity is particularly challenging in elderly patients with PCNSL. In this study, we attempt to characterize the prognostic factors of treatment and outcome of a large cohort of older patients treated at Memorial Sloan-Kettering Cancer Center (MSKCC). MATERIALS AND METHODS Study Design The MSKCC institutional database was used to identify patients with PCNSL diagnosed between January 1, 1986, and December 31, Inclusion criteria included histologically confirmed PCNSL and age 65 years at the time of diagnosis. The date of the surgical procedure leading to a definitive pathologic diagnosis was used as the date of diagnosis. Data were collected by chart review. We examined the impact of demographic variables on the probability of receiving chemotherapy, WBRT, or both. Response to treatment was defined as complete disappearance of all contrast-enhancing lesions on magnetic resonance imaging or computed tomography when the patient was no longer receiving glucocorticoids (complete response [CR]) or a 50% decrease in enhancing disease on stable or decreasing doses of glucocorticoids (partial response [PR]). This retrospective study was approved by the MSKCC Institutional Review Board. Statistical Analyses Demographic and clinical variables studied included patient sex, age, Karnofsky performance score (KPS), year of diagnosis, marital status, CSF total protein, deep brain involvement, serum lactate dehydrogenase (LDH) level, hemiparesis, and history of prior cancer. Age at diagnosis was analyzed as a categorical variable. Age trends were assessed using an ordinal age at diagnosis variable. The following variables were dichotomized in the analysis: CSF total protein, KPS, serum LDH, and year of diagnosis. The year 1998 was used as the cutpoint for year of diagnosis because we had eliminated the routine use of WBRT in the initial treatment of older patients by that time. Therapy included any chemotherapy treatment, any radiation treatment, and a combined variable of having been treated with both chemotherapy and RT. Unadjusted logistic regression models were used to analyze demographic and clinical predictors of receipt of treatment. Multivariate logistic regression models were used to analyze those demographic and clinical predictors of receipt of treatment that were univariately significant at the a <.10 level. The association between clinically defined neurotoxicity and WBRT was examined in a landmark analysis at 2 years from diagnosis. Neurotoxicity events occurring after 2 years, as well as patients who were not alive and followed for 2 years, were not included in the analysis. The selection of 2 years was based on the median overall survival of the cohort. A landmark analysis was performed to ensure that those included in the analysis had sufficient follow-up to develop neurotoxicity without death as a competing event. Overall survival was examined from the date of diagnosis to date of death or last follow-up. Univariate Cox proportional hazards models were fit to analyze predictors of survival. A multivariate Cox proportional hazard model was used to analyze predictors of survival that were univariately significant at the a <.10 level. All statistical analyses were performed using SAS statistical software (version 9.1; SAS Institute Inc, Cary, NC). RESULTS Patient Characteristics One hundred seventy-four patients aged 65 years who were diagnosed with PCNSL between 1986 and 2008 were included (Table 1). The median age at diagnosis was 72 years (range, years); there was a predominance of women (52.9%). Most patients were diagnosed before 1998 (62.6%), and a majority of patients were married 4606 Cancer October 1, 2010
3 PCNSL in the Elderly/Ney et al Table 1. Patient Demographics Characteristic No. of Patients % Age at diagnosis, y Sex Men Women Y of diagnosis Prior to and after Marital status Married Unmarried KPS at presentation < Unknown CSF total protein, mg/dl > Missing Deep brain involvement No Yes Missing Serum LDH, U/L > Missing Hemiparesis No Yes Missing History of prior malignancy No Yes Missing KPS indicates Karnofsky performance status; CSF, cerebrospinal fluid; LDH, lactate dehydrogenase. (67.2%). Forty-six (26.4%) patients had a history of a prior nonlymphomatous malignancy. Treatment at Diagnosis One hundred seventeen patients (67.2%) received chemotherapy alone, 16 (9.2%) patients received RT alone, and 31 (17.8%) patients received both chemotherapy and RT (Table 2). Six patients received no treatment, and data regarding therapy were missing for 4 patients. Of the 148 patients who received chemotherapy, 145 (98%) received Table 2. Initial Treatment for Elderly Patients With PCNSL Treatment No. % Chemotherapy alone Radiotherapy alone Chemotherapy þ radiotherapy No treatment Missing PCNSL indicates primary central nervous system lymphoma. high-dose methotrexate (at a dose of 3.5 g/m 2 ); response to chemotherapy (CR þ PR) was noted in 76% of these patients. Predictors of Treatment Significant univariate predictors of receipt of chemotherapy were age at diagnosis, year of diagnosis, and deep brain involvement. Patients who were diagnosed in 1998 and later were more likely to receive chemotherapy (odds ratio [OR], 3.4; 95% confidence interval [95% CI], ) as were patients with deep brain involvement (OR, 4.6; 95% CI, ). There was also a trend noted with age in which older patients were more likely to receive chemotherapy (P ¼.07). In the multivariate analysis for predictors of chemotherapy treatment, only deep brain involvement was found to be significant (OR, 4.5; 95% CI, ), adjusting for age at diagnosis and year of diagnosis. Significant univariate predictors of receipt of RT included age at diagnosis, year of diagnosis, marital status, deep brain involvement, and history of prior cancer. Patients were significantly less likely to receive RT if they were older, diagnosed in 1998 or later, unmarried, had deep brain involvement, or had at least 1 prior cancer. In the multivariate setting, those patients who were diagnosed in 1998 or later were less likely to receive RT (hazard ratio [HR], 0.2; 95% CI, ) as were those with at least 1 prior cancer (HR, 0.2; 95% CI, ). Marital status remained of borderline significance (P ¼.06) as did a trend for age (P ¼.06). Other results for the analyses of predictors of PCNSL treatment can be seen in Table 3. Survival Analysis The median overall survival for the entire cohort was 25 months (95% CI, months) (Fig. 1). The 3-year survival rate was 36% (95% CI, 29%-44%). Ninety patients (52%) developed disease progression with a median time to disease progression of 24 months (95% CI, months); 74 of these 90 patients (82.2%) received salvage therapy, 53 received chemotherapy alone, 14 received Cancer October 1,
4 Table 3. Predictors of Receiving Preradiation Chemotherapy, Radiotherapy, and Both Modalities for the Elderly PCNSL Cohort Variable Level Unadjusted Chemotherapy Radiotherapy Both Radiotherapy and Chemotherapy P a Adjusted b P a Unadjusted P a Adjusted b P a Unadjusted P a Adjusted b P a Age categories, y ( ) 3.4 ( ) 0.7 ( ) 0.9 ( ) 1.0 ( ) 1.7 ( ) ( ) 1.7 ( ) 0.4 ( ) 0.5 ( ) 0.5 ( ) 0.9 ( ) ( ) 2.4 ( ) 0.1 ( ) 0.2 ( ) No estimate c No estimate c Sex Male Female 0.6 ( ) 0.9 ( ) 0.7 ( ) Y of diagnosis Prior to < < < and after 3.4 ( ) 1.1 ( ) 0.1 ( ) 0.2 ( ) 0.1 ( ) 0.1 ( ) Marital status Married Unmarried 0.7 ( ) 0.4 ( ) 0.4 ( ) 0.2 ( ) 0.2 ( ) KPS < ( ) 1.3 ( ) 1.1 ( ) CSF total protein, mg/dl > ( ) 1.1 ( ) 0.8 ( ) Deep brain involvement No Yes 4.6 ( ) 4.3 ( ) 0.4 ( ) 0.8 ( ) 0.5 ( ) Serum LDH, U/L > ( ) 1.2 ( ) 1.2 ( ) Hemiparesis No Yes 0.7 ( ) 1.5 ( ) 0.9 ( ) History of prior cancer No Yes 0.7 ( ) 0.3 ( ) 0.2 ( ) 0.2 ( ) 0.2 ( ) PCNSL indicates primary central nervous system lymphoma; OR, odds ratio; 95% CI, 95% confidence interval; KPS, Karnofsky performance status; CSF, cerebrospinal fluid; LDH, lactate dehydrogenase. a P value is for trend for age variable. b Adjusted for other variables in the multivariate logistic model. Variables were entered into the multivariate model if univariately significant (at a <0.1 level). c No estimate because there were no subjects who received both preradiation chemotherapy and radiotherapy who were aged 80 years Cancer October 1, 2010
5 PCNSL in the Elderly/Ney et al Toxicity Acute treatment-related toxicity was not collected prospectively in all patients. However, NCI CTCAEv 3.0 grades 3 and 4 nephrotoxicity related to high-dose methotrexate was noted in 13 of the 145 patients treated (9%); this is a minimal incidence. There was no grade 5 nephrotoxicity. There were 77 patients alive 2 years from diagnosis. Eighteen (23%) developed neurotoxicity, 67% of whom received RT. This is in contrast to 55 patients who survived 2 years and never developed neurotoxicity, 18% of whom received RT (P ¼.0002). There were 4 patients alive at 2 years who developed neurotoxicity after that timepoint and whose neurotoxicity events were excluded. Figure 1. (Top) Overall survival of the Memorial Sloan-Kettering Cancer Center cohort of 174 older patients with primary central nervous system lymphoma is shown. (Bottom) Overall survival from the Surveillance, Epidemiology, and End Results (SEER)-Medicare study is shown. DOD indicates died of disease; 95% CI, 95% confidence interval. Reproduced with permission from Panageas KS, Elkin EB, Ben-Porat L, DeAngelis LM, Abrey LE. Patterns of treatment in older adults with primary central nervous system lymphoma. Cancer. Vol. 110, No. 6, 2007, VC 2007 American Cancer Society. This material is reproduced with permission of Wiley-Liss, Inc, a subsidiary of John Wiley & Sons, Inc. RT, and 7 received both. Radiographic response (CR þ PR) was noted in 48% of patients receiving salvage treatment. Thirty-nine patients were alive at a median followup of 34 months, and their treatment was comparable to the group as a whole. Thirty-five (89.7%) of these patients were diagnosed before 1998 and represent long-term survivors; these 35 patients were 20.1% of the entire cohort. Age at diagnosis and KPS were found to be the only 2 significant predictors of overall survival in the univariate analysis (Table 4). In the multivariate model, increasing age demonstrated a significant trend (P ¼.03) toward a greater probability of death. Patients with a KPS 70 were significantly less likely to die (P <.0001). DISCUSSION The results of the current study demonstrate that vigorous therapy of elderly patients with PCNSL can produce prolonged survival in a significant percentage. The data from the current study represent a selected patient population that may not reflect the elderly population in the community; however, nearly 10% of our patients were aged 80 years and nearly 40% had a KPS of 60atthetimeofdiagnosis. Despite these clinical features, 96.5% of our patients received therapy, which is a much higher percentage than noted in the SEER-Medicare cohort or the general British Columbia population, most likely reflecting our vigorous approach to these patients. 21,22 Furthermore, 83% (145 of 174 patients) were treated with high-dose methotrexate. In general, treatment was well tolerated and the majority responded. Even at the time of disease recurrence, 48% of patients responded to salvage therapy. These data demonstrate that many elderly patients can, and should, receive a treatment regimen comparable to that which is often reserved for younger patients. Age is the most influential prognostic factor in PCNSL and invariably affects treatment decisions. 19,21,23 The SEER-Medicare data indicated that 20% of all older patients are not treated at all. 21 In a large populationbased study in British Columbia, 10.7% of all PCNSL patients seen in that province between 1990 and 2003 received steroids only and no definitive treatment; the majority were older patients. 22 Furthermore, when treatment was administered, it was often suboptimal. WBRT was the sole therapy for 36% of patients in the SEER-Medicare database, 17% received chemotherapy alone, and 26% received both. 21 The median survival of the SEER- Medicare cohort was 7 months, comparable to the 7.6 Cancer October 1,
6 Table 4. Predictors of Overall Survival for the Elderly PCNSL Cohort Treated at MSKCC Variable Level Unadjusted HR (95% CI) P a Adjusted b HR (95% CI) P a Sex Male Female 1.0 ( ) Age categories, y ( ) 1.1 ( ) ( ) 1.3 ( ) ( ) 2.0 ( ) Y of diagnosis Prior to and after 0.9 ( ) Marital status Married Unmarried 1.2 ( ) CSF total protein, mg/dl > ( ) Deep brain involvement No Yes 1.2 ( ) KPS < < < ( ) 0.5 ( ) Serum LDH, U/L > ( ) Hemiparesis No Yes 1.2 ( ) History of prior cancer No Yes 0.9 ( ) PCNSL indicates primary central nervous system lymphoma; MSKCC, Memorial Sloan-Kettering Cancer Center; HR, hazard ratio; 95% CI, 95% confidence interval; CSF, cerebrospinal fluid; KPS, Karnofsky performance status; LDH, lactate dehydrogenase. a P value was for trend for age variable. b Adjusted for other variables in the multivariate logistic model. Variables were entered into the multivariate model if univariately significant (at a <0.1 level). months achieved with WBRT alone in patients aged 60 years. 6,21 Outcome is superior when chemotherapy is part of the initial treatment plan. In a comparably aged population, high-dose methotrexate-based chemotherapy with or without WBRT achieved a median overall survival of 29 months in those patients aged >60 years, which is similar to the 25-month median survival noted in our cohort. 18 The majority of patients in our elderly cohort received chemotherapy alone as initial treatment. Approximately 83% of our total population and 98% of those who received any chemotherapy received methotrexate (at a dose of 3.5 g/m 2 ). This reflects the aggressive approach of a tertiary referral center accustomed to using high doses of chemotherapy for this disease despite the poor performance status of many patients. For many older patients, it has been well demonstrated that methotrexate-based regimens are tolerable and effective One study demonstrated no significant difference between methotrexate (at a dose of 4 g/m 2 )-related toxicities in patients aged 60 years versus those aged <60 years. 26 Similarly, a recent retrospective review of patients aged 70 years who were treated with high-dose methotrexate (at a dose of 8 g/m 2 ) demonstrated that this regimen was well tolerated and produced radiographic response rates of >90%, and that few patients required discontinuation of chemotherapy for toxicity. 27 Although numerous studies have demonstrated the efficacy of methotrexate-based regimens, to the best of our knowledge no phase 3 trial has been conducted to date to demonstrate the superiority of any particular regimen. However, methotrexate appears to be well tolerated in the elderly, supporting its use in these patients. The late complications of combined modality therapy, namely neurotoxicity and dementia, were first recognized in the late 1990s. The results of the current study demonstrated significantly less use of WBRT in patients treated in 1998 or later. Despite this trend, the year of treatment appeared to have no effect on survival, suggesting that chemotherapy alone may be a good choice for the initial treatment of PCNSL in the elderly. Radiographic responses, time to disease progression, and overall survival were found to be similar to the results of prior studies using methotrexate-based regimens. 12,17,18,24,25,27 Recent data suggest that consolidation with low doses of RT after 4610 Cancer October 1, 2010
7 PCNSL in the Elderly/Ney et al immunochemotherapy may improve upon survival without the risk of neurotoxicity. 28,29 However, longer followup and additional studies are needed. Other than year of diagnosis, few sociodemographic characteristics were found to predict treatment. Married patients were more likely to receive both chemotherapy and RT, which was also found in the SEER-Medicare dataset, perhaps suggesting that patients with strong social support are more likely to receive aggressive therapy. Our sample size was relatively small and may not have been powered to detect small but significant associations between other patient characteristics and treatment received. The current study has several limitations, including the inherent biases of a retrospective study. Other important variables including treatment toxicity, quality of life measures, and detailed neurocognitive assessments on all patients were not available. Referral and treatment practice biases are almost certainly inherent in this single-center cohort. Nonetheless, this study reflects a relatively large group of older patients with a rare disease, specifically examining patterns of care, prognostic factors, and outcomes of specialized treatment practices as they apply to the elderly PCNSL population. Although outcome is worse in older patients with PCNSL, that should not preclude the use of aggressive therapy because the majority of patients respond and improve clinically. The patients in the current study cohort had a favorable time to disease progression, and greater than half responded to salvage therapy. Clinical trials aimed at this population are crucial to improving outcomes associated with this disease, and patients should be referred to institutions with an interest in PCNSL for inclusion into these studies. CONFLICT OF INTEREST DISCLOSURES The authors made no disclosures. REFERENCES 1. Central Brain Tumor Registry of the United States. Statistical report: primary brain tumors in the United States, Hinsdale, IL: Central Brain Tumor Registry of the United States; Olson JE, Janney CA, Rao RD, et al. The continuing increase in the incidence of primary central nervous system non-hodgkin lymphoma: a surveillance, epidemiology, and end results analysis. Cancer. 2002;95: Wolf T, Brodt HR, Fichtlscherer S, et al. Changing incidence and prognostic factors of survival in AIDS-related non-hodgkin s lymphoma in the era of highly active antiretroviral therapy (HAART). Leuk Lymphoma. 2005;46: Kadan-Lottick NS, Skluzacek MC, Gurney JG. Decreasing incidence rates of primary central nervous system lymphoma. Cancer. 2002;95: Ekenel M, DeAngelis LM. Treatment of primary central nervous system lymphoma. Curr Neurol Neurosci Rep. 2007; 7: Nelson DF, Martz KL, Bonner H, et al. Non-Hodgkin s lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG Int J Radiat Oncol Biol Phys. 1992;23: Abrey LE, Yahalom J, DeAngelis LM. Treatment for primary CNS lymphoma: the next step. J Clin Oncol. 2000;18: Batchelor T, Carson K, O Neill A, et al. Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT J Clin Oncol. 2003;21: DeAngelis LM, Yahalom J, Thaler HT, et al. Combined modality therapy for primary CNS lymphoma. J Clin Oncol. 1992;10: DeAngelis LM Seiferheld W, Schold SC, et al. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group J Clin Oncol. 2002;20: Herrlinger U, Kuker W, Uhl M, et al. NOA-03 trial of high-dose methotrexate in primary central nervous system lymphoma: final report. Ann Neurol. 2005;57: Hoang-Xuan K, Taillandier L, Chinot O, et al. Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group. J Clin Oncol. 2003;21: O Neill BP, Wang CH, O Fallon JR, et al. Primary central nervous system non-hodgkin s lymphoma (PCNSL): survival advantages with combined initial therapy? A final report of the North Central Cancer Treatment Group (NCCTG) Study Int J Radiat Oncol Biol Phys. 1999;43: Sandor V, Stark-Vancs V, Pearson D, et al. Phase II trial of chemotherapy alone for primary CNS and intraocular lymphoma. J Clin Oncol. 1998;16: Wu HG, Kim IH, Ha SW, et al. Survival improvement with combined radio-chemotherapy in the primary central nervous system lymphomas. J Korean Med Sci. 1999;14: Omuro AM, Ben-Porat LS, Panageas KS, et al. Delayed neurotoxicity in primary central nervous system lymphoma. Arch Neurol. 2005;62: Freilich RJ, Delattre JY, Monjour A, et al. Chemotherapy without radiation therapy as initial treatment for primary CNS lymphoma in older patients. Neurology. 1996;46: Gavrilovic IT, Hormigo A, Yahalom J, et al. Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol. 2006;24: Abrey LE, Ben-Porat L, Panageas KS, et al. Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol. 2006;24: Cancer October 1,
8 20. Corry J, Smith JG, Wirth A, et al. Primary central nervous system lymphoma: age and performance status are more important than treatment modality. Int J Radiat Oncol Biol Phys. 1998;41: Panageas KS, Elkin EB, Ben-Porat L, Deangelis LM, Abrey LE. Patterns of treatment in older adults with primary central nervous system lymphoma. Cancer. 2007;110: Shenkier TN, Voss N, Chhanabhai M, et al. The treatment of primary central nervous system lymphoma in 122 immunocompetent patients. A population-based study of successively treated cohorts from the British Columbia Cancer Agency. Cancer. 2005;103: Panageas KS, Elkin EB, DeAngelis LM, et al. Trends in survival from primary central nervous system lymphoma, : a population-based analysis. Cancer. 2005;104: Ng S, Rosenthal MA, Ashley D, Cher L. High-dose methotrexate for primary CNS lymphoma in the elderly. Neuro Oncol. 2000;2: Omuro AM, Taillandier L, Chinot O, et al. Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly. JNeurooncol.2007;85: Jahnke K, Korfel A, Martus P, et al. High-dose methotrexate toxicity in elderly patients with primary central nervous system lymphoma. Ann Oncol. 2005;16: Zhu JJ, Gerstner ER, Engler DA, et al. High-dose methotrexate for elderly patients with primary CNS lymphoma. Neuro Oncol. 2009;11: Correa DD, Rocco-Donovan M, DeAngelis LM, et al. Prospective cognitive follow-up in primary CNS lymphoma patients treated with chemotherapy and reduced-dose radiotherapy. J Neurooncol. 2009;91: Shah GD, Yahalom JJ, Correa DD, et al. Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol. 2007;25: Cancer October 1, 2010
Primary central nervous system lymphoma (PCNSL)
Neuro-Oncology 14(10):1304 1311, 2012. doi:10.1093/neuonc/nos207 Advance Access publication September 5, 2012 NEURO-ONCOLOGY Outcomes of the oldest patients with primary CNS lymphoma treated at Memorial
More informationJ Clin Oncol 23: by American Society of Clinical Oncology INTRODUCTION
VOLUME 23 NUMBER 7 MARCH 1 2005 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Results of Whole-Brain Radiation As Salvage of Methotrexate Failure for Immunocompetent Patients With Primary CNS
More informationAn Update on Therapy of Primary Central Nervous System Lymphoma
An Update on Therapy of Primary Central Nervous System Lymphoma Lisa M. DeAngelis and Fabio M. Iwamoto Primary central nervous system lymphoma (PCNSL) is an extranodal non-hodgkin lymphoma (NHL) that arises
More informationIAN CROCKER = TIM HOWARD
Winship Cancer Institute of Emory University Radiation as Consolidation in the Treatment of Newly Diagnosed CNS Lymphoma versus After Failure of Chemotherapy Pro: Upfront Radiation Ian Crocker MD, FACR,
More informationPrimary CNS lymphoma in HIV positive and negative patients: comparison of clinical characteristics, outcome and prognostic factors
J Neurooncol (2011) 101:257 265 DOI 10.1007/s11060-010-0252-3 CLINICAL STUDY PATIENT STUDY Primary CNS lymphoma in HIV positive and negative patients: comparison of clinical characteristics, outcome and
More informationHigh-dose methotrexate toxicity in elderly patients with primary central nervous system lymphoma
Original article Annals of Oncology 16: 445 449, 2005 doi:10.1093/annonc/mdi075 Published online 14 January 2005 High-dose methotrexate toxicity in elderly patients with primary central nervous system
More informationPopulation-Based Incidence and Survival for Primary Central Nervous System Lymphoma in Korea,
pissn 1598-2998, eissn 2005-9256 Cancer Res Treat. 2015;47(4):569-574 Original Article http://dx.doi.org/10.4143/crt.2014.085 Open Access Population-Based Incidence and Survival for Primary Central Nervous
More informationTherapy and outcomes of primary central nervous system lymphoma in the United States: analysis of the National Cancer Database
REGULAR ARTICLE Therapy and outcomes of primary central nervous system lymphoma in the United States: analysis of the National Cancer Database Jaleh Fallah, 1,2 Lindor Qunaj, 1 and Adam J. Olszewski 1,3
More informationCognitive functions in primary CNS lymphoma after single or combined modality regimens
Neuro-Oncology 14(1):101 108, 2012. doi:10.1093/neuonc/nor186 Advance Access publication October 19, 2011 NEURO-ONCOLOGY Cognitive functions in primary CNS lymphoma after single or combined modality regimens
More informationPRIMARY CNS lymphoma (PCNSL) is a rare non-
Treatment of Primary CNS Lymphoma With Methotrexate and Deferred Radiotherapy: A Report of NABTT 96 07 By Tracy Batchelor, Kathryn Carson, Alison O Neill, Stuart A. Grossman, Jane Alavi, Pamela New, Fred
More informationPublished Ahead of Print on May 18, 2009 as /JCO J Clin Oncol by American Society of Clinical Oncology INTRODUCTION
Published Ahead of Print on May 18, 29 as 1.12/JCO.28.19.3789 The latest version is at http://jco.ascopubs.org/cgi/doi/1.12/jco.28.19.3789 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Blood-Brain
More informationUPDATES ON CHEMOTHERAPY FOR LOW GRADE GLIOMAS
UPDATES ON CHEMOTHERAPY FOR LOW GRADE GLIOMAS Antonio M. Omuro Department of Neurology Memorial Sloan-Kettering Cancer Center II International Neuro-Oncology Congress Sao Paulo, 08/17/12 CHALLENGES IN
More informationMANAGEMENT N OF PRIMARY BRAIN TUMOURS IN THE ELDERLY
MANAGEMENT N OF PRIMARY BRAIN TUMOURS IN THE ELDERLY Meningioma, Glioma, Lymphoma Cornu Ph, Keime-Guibert F, Hoang-Xuan K, Pierga JY, Delattre JY Neuro-oncology Group of Pitie-Salpetriere hospital-paris-france
More informationTheresa Keegan, Ph.D., M.S. Associate Professor Department of Internal Medicine Division of Hematology and Oncology
Impact of treatment and insurance on socioeconomic disparities in survival after adolescent and young adult Hodgkin lymphoma: A population- based study Theresa Keegan, Ph.D., M.S. Associate Professor Department
More informationORIGINAL CONTRIBUTION
ORIGINAL CONTRIBUTION Delayed Neurotoxicity in Primary Central Nervous System Lymphoma Antonio M. P. Omuro, MD; Leah S. Ben-Porat, MS; Katherine S. Panageas, DrPH; Amy K. Kim, BA; Denise D. Correa, PhD;
More informationTreatment disparities for patients diagnosed with metastatic bladder cancer in California
Treatment disparities for patients diagnosed with metastatic bladder cancer in California Rosemary D. Cress, Dr. PH, Amy Klapheke, MPH Public Health Institute Cancer Registry of Greater California Introduction
More informationRecent Advances in Treatment of Primary Central Nervous System Lymphoma
Current Treatment Options in Oncology (2013) 14:539 552 DOI 10.1007/s11864-013-0252-6 Neuro-oncology (GJ Lesser, Section Editor) Recent Advances in Treatment of Primary Central Nervous System Lymphoma
More informationImproved Survival in Patients With Early Stage Low-Grade Follicular Lymphoma Treated With Radiation
Original Article Improved Survival in Patients With Early Stage Low-Grade Follicular Lymphoma Treated With Radiation A Surveillance, Epidemiology, and End Results Database Analysis Thomas J. Pugh, MD;
More informationA Population-Based Study on the Uptake and Utilization of Stereotactic Radiosurgery (SRS) for Brain Metastasis in Nova Scotia
A Population-Based Study on the Uptake and Utilization of Stereotactic Radiosurgery (SRS) for Brain Metastasis in Nova Scotia Gaurav Bahl, Karl Tennessen, Ashraf Mahmoud-Ahmed, Dorianne Rheaume, Ian Fleetwood,
More informationAppendix 2. List of the thirty-two studies included in qualitative synthesis, (Online only)
Appendix 2. List of the thirty-two studies included in qualitative synthesis, (Online only) 1. Mead GM, Bleehen NM, Gregor A, Bullimore J, Shirley D, Rampling RP, et al. A medical research council randomized
More informationJ Clin Oncol 24: by American Society of Clinical Oncology INTRODUCTION
VOLUME 24 NUMBER 24 AUGUST 20 2006 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T High-Dose Chemotherapy With Autologous Stem-Cell Transplantation and Hyperfractionated Radiotherapy As First-Line
More informationRadiotherapy in aggressive lymphomas. Umberto Ricardi
Radiotherapy in aggressive lymphomas Umberto Ricardi Is there (still) a role for Radiation Therapy in DLCL? NHL: A Heterogeneous Disease ALCL PMLBCL (2%) Burkitt s MCL (6%) Other DLBCL (31%) - 75% of aggressive
More informationSurvival and Intracranial Control of Patients With 5 or More Brain Metastases Treated With Gamma Knife Stereotactic Radiosurgery
ORIGINAL ARTICLE Survival and Intracranial Control of Patients With 5 or More Brain Metastases Treated With Gamma Knife Stereotactic Radiosurgery Ann C. Raldow, BS,* Veronica L. Chiang, MD,w Jonathan P.
More informationA DISSERTATION SUBMITTED TO THE FACULTY OF THE GRADUATE SCHOOL OF THE UNIVERSITY OF MINNESOTA BY. Helen Mari Parsons
A Culture of Quality? Lymph Node Evaluation for Colon Cancer Care A DISSERTATION SUBMITTED TO THE FACULTY OF THE GRADUATE SCHOOL OF THE UNIVERSITY OF MINNESOTA BY Helen Mari Parsons IN PARTIAL FULFILLMENT
More informationA Case of Primary Central Nervous System Lymphoma Located at Brain Stem in a Child
CSE REPORT rain Tumor Res Treat 2016;4(2):155-159 / pissn 2288-2405 / eissn 2288-2413 http://dx.doi.org/10.14791/btrt.2016.4.2.155 Case of Primary Central Nervous System Lymphoma Located at rain Stem in
More informationCerebral Lymphoma: Clinical and Radiological Findings in 90 Cases
Arch Iranian Med 27; 1 (2): 194 198 Original Article Cerebral Lymphoma: Clinical and Radiological Findings in 9 Cases Alireza Zali MD *, Sohrab Shahzadi MD*, Alireza Mohammad-Mohammadi MD*, Karim Taherzadeh
More informationRadiotherapy in DLCL is often worthwhile. Dr. Joachim Yahalom Memorial Sloan-Kettering, New York
Radiotherapy in DLCL is often worthwhile Dr. Joachim Yahalom Memorial Sloan-Kettering, New York The case for radiotherapy Past: Pre-Rituximab randomized trials Present: R-CHOP as backbone, retrospective
More informationCharacterization of Patients with Poor-
Characterization of Patients with Poor- Risk Metastatic Renal Cell Carcinoma Hamieh L 1 *, McKay RR 1 *, Lin X 2, Simantov R 2, Choueiri TK 1 *Equal contributions 1 Dana-Farber Cancer Institute, Boston,
More informationPROCARBAZINE, lomustine, and vincristine (PCV) is
RAPID PUBLICATION Procarbazine, Lomustine, and Vincristine () Chemotherapy for Anaplastic Astrocytoma: A Retrospective Review of Radiation Therapy Oncology Group Protocols Comparing Survival With Carmustine
More informationPolicy for Central Nervous System [CNS] Prophylaxis in Lymphoid Malignancies
Policy for Central Nervous System [CNS] Prophylaxis in Lymphoid Malignancies UNCONTROLLED WHEN PRINTED Note: NOSCAN Haematology MCN has approved the information contained within this document to guide
More informationSystemic Treatment. Third International Neuro-Oncology Course. 23 May 2014
Low-Grade Astrocytoma of the CNS: Systemic Treatment Third International Neuro-Oncology Course São Paulo, Brazil 23 May 2014 John de Groot, MD Associate Professor, Neuro-Oncology UT MD Anderson Cancer
More informationJulien Cobert Ephraim Hochberg Nina Woldenberg Fred Hochberg
J Neurooncol (2010) 98:385 393 DOI 10.1007/s11060-009-0090-3 CLINICAL STUDY - PATIENT STUDY Monotherapy with methotrexate for primary central nervous lymphoma has single agent activity in the absence of
More informationPulczynski, Elisa J
https://helda.helsinki.fi Successful change of treatment strategy in elderly patients with primary central nervous system lymphoma by de-escalating induction and introducing temozolomide maintenance Pulczynski,
More informationModified Number of Extranodal Involved Sites as a Prognosticator in R-CHOP-Treated Patients with Disseminated Diffuse Large B-Cell Lymphoma
ORIGINAL ARTICLE DOI: 10.3904/kjim.2010.25.3.301 Modified Number of Extranodal Involved Sites as a Prognosticator in R-CHOP-Treated Patients with Disseminated Diffuse Large B-Cell Lymphoma Changhoon Yoo
More informationRadiotherapy as an alternative treatment option for primary central nervous system lymphoma patients who are noncandidates for chemotherapy
/, 2017, Vol. 8, (No. 63), pp: 106858-106865 Radiotherapy as an alternative treatment option for primary central nervous system lymphoma patients who are noncandidates for chemotherapy Yoo-Kang Kwak 1,
More informationPrimary central nervous system lymphoma treated with high dose methotrexate and rituximab: A single institution experience
ONCOLOGY LETTERS 11: 3471-3476, 2016 Primary central nervous system lymphoma treated with high dose methotrexate and rituximab: A single institution experience K. INA LY 1, LAURA L. CREW 2, CARRIE A. GRAHAM
More informationOutcomes of patients with peripheral T-cell lymphoma in first complete remission: data from three tertiary Asian cancer centers
Tang et al. (2017) 7:653 DOI 10.1038/s41408-017-0030-y CORRESPONDENCE Outcomes of patients with peripheral T-cell lymphoma in first complete remission: data from three tertiary Asian cancer centers Open
More informationCCSS Concept Proposal Working Group: Biostatistics and Epidemiology
Draft date: June 26, 2010 CCSS Concept Proposal Working Group: Biostatistics and Epidemiology Title: Conditional Survival in Pediatric Malignancies: A Comparison of CCSS and SEER Data Proposed Investigators:
More informationBreast Cancer in Childhood Cancer Survivors: The Impact of Screening on Morbidity
Breast Cancer in Childhood Cancer Survivors: The Impact of Screening on Morbidity WORKING GROUP: This report will be written within the Cancer Control Working Group with oversight from the Second Malignant
More informationNeuro-Oncology Practice
Neuro-Oncology Practice Neuro-Oncology Practice 3(2), 71 76, 2016 doi:10.1093/nop/npv043 Advance Access date 16 October 2015 Anaplastic astrocytoma and non-1p/19q co-deleted anaplastic oligoastrocytoma:
More informationArecent randomized controlled trial (RCT) established
Neuro-Oncology 12(2):190 198, 2010. doi:10.1093/neuonc/nop004 NEURO-ONCOLOGY The timing of cranial radiation in elderly patients with newly diagnosed glioblastoma multiforme Rose Lai, Dawn L. Hershman,
More informationPrimary central nervous system lymphoma
Primary central nervous system lymphoma Tracy T. Batchelor LYMPHOMA: CHALLENGES AND NEW DIRECTIONS Departments of Neurology and Radiation Oncology, Division of Hematology/Oncology, Massachusetts General
More informationExercise Behavior & Major Cardiac Events: CCSS 1 STUDY TITLE
STUDY TITLE Exercise Behavior & Major Cardiac Events: CCSS 1 Association Between Exercise Behavior and Incidence of Major Cardiac Events in Adult Survivors of Childhood Cancer: A Report from the Childhood
More informationAnalysis of the outcome of young age tongue squamous cell carcinoma
Jeon et al. Maxillofacial Plastic and Reconstructive Surgery (2017) 39:41 DOI 10.1186/s40902-017-0139-8 Maxillofacial Plastic and Reconstructive Surgery RESEARCH Open Access Analysis of the outcome of
More informationUsing claims data to investigate RT use at the end of life. B. Ashleigh Guadagnolo, MD, MPH Associate Professor M.D. Anderson Cancer Center
Using claims data to investigate RT use at the end of life B. Ashleigh Guadagnolo, MD, MPH Associate Professor M.D. Anderson Cancer Center Background 25% of Medicare budget spent on the last year of life.
More informationSelecting the Optimal Treatment for Brain Metastases
Selecting the Optimal Treatment for Brain Metastases Clinical Practice Today CME Co-provided by Learning Objectives Upon completion, participants should be able to: Understand the benefits, limitations,
More informationSupplementary Appendix to manuscript submitted by Trappe, R.U. et al:
Supplementary Appendix to manuscript submitted by Trappe, R.U. et al: Response to rituximab induction is a predictive marker in B-cell post-transplant lymphoproliferative disorder and allows successful
More informationHyponatremia in small cell lung cancer is associated with a poorer prognosis
Original Article Hyponatremia in small cell lung cancer is associated with a poorer prognosis Wenxian Wang 1, Zhengbo Song 1,2, Yiping Zhang 1,2 1 Department of Chemotherapy, Zhejiang Cancer Hospital,
More informationProphylactic Mastectomy State of the Art
Memorial Sloan-Kettering Cancer Center 1275 York Avenue, New York, NY 10065 6 th Brazilian Breast Cancer Conference Sao Paulo, Brazil 9 March 2012 Prophylactic Mastectomy State of the Art Monica Morrow
More information성균관대학교삼성창원병원신경외과학교실신경종양학 김영준. KNS-MT-03 (April 15, 2015)
성균관대학교삼성창원병원신경외과학교실신경종양학 김영준 INTRODUCTIONS Low grade gliomas (LGG) - heterogeneous group of tumors with astrocytic, oligodendroglial, ependymal, or mixed cellular histology - In adults diffuse, infiltrating
More informationResearch Article Prognostic Factors in Advanced Non-Small-Cell Lung Cancer Patients: Patient Characteristics and Type of Chemotherapy
SAGE-Hindawi Access to Research Lung Cancer International Volume 2011, Article ID 152125, 4 pages doi:10.4061/2011/152125 Research Article Prognostic Factors in Advanced Non-Small-Cell Lung Cancer Patients:
More informationBy Hatice Terzi, Çağrı Canbolat, Hüseyin Bozkurt, Serdal Korkmaz, Ünal Özüm, Özen Karadağ & Mehmet Sencan Cumhuriyet University
: F Diseases Volume 7 Issue Version.0 Year 07 Type: Double Blind Peer Reviewed International Research Journal Publisher: Global Journals Inc. (USA) Online ISSN: 968 & Print ISSN: 097888 Characteristics
More informationSummary BREAST CANCER - Early Stage Breast Cancer... 3
ESMO 2016 Congress 7-11 October, 2016 Copenhagen, Denmark Table of Contents Summary... 2 BREAST CANCER - Early Stage Breast Cancer... 3 Large data analysis reveals similar survival outcomes with sequential
More informationImproving outcomes for NSCLC patients with brain metastases
Improving outcomes for NSCLC patients with brain metastases Martin Schuler West German Cancer Center, Essen, Germany In Switzerland, afatinib is approved as monotherapy for patients with non-small cell
More informationManagement of single brain metastasis: a practice guideline
PRACTICE GUIDELINE SERIES Management of single brain metastasis: a practice guideline A. Mintz MD,* J. Perry MD, K. Spithoff BHSc, A. Chambers MA, and N. Laperriere MD on behalf of the Neuro-oncology Disease
More information2007 ANNUAL SITE STUDY HODGKIN S LYMPHOMA
2007 ANNUAL SITE STUDY HODGKIN S LYMPHOMA SUSQUEHANNA HEALTH David B. Nagel, M.D. April 11, 2008 Hodgkin s lymphoma was first described by Thomas Hodgkin in 1832. It remained an incurable malignancy until
More informationRole of Prophylactic Cranial Irradiation in Small Cell Lung Cancer
Role of Prophylactic Cranial Irradiation in Small Cell Lung Cancer Kazi S. Manir MD,DNB,ECMO,PDCR Clinical Tutor Department of Radiotherapy R. G. Kar Medical College and Hospital, Kolkata SCLC 15% of lung
More informationTreatment and prognostic analysis of patients with leptomeningeal metastases from non-small cell lung cancer
Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Treatment and prognostic analysis of patients with leptomeningeal metastases from non-small cell lung cancer Qinghua Xu 1,6, Xiu Chen 3, Danwen Qian 4, Yongsheng
More informationSociodemographic and Clinical Predictors of Triple Negative Breast Cancer
University of Kentucky UKnowledge Theses and Dissertations--Public Health (M.P.H. & Dr.P.H.) College of Public Health 2017 Sociodemographic and Clinical Predictors of Triple Negative Breast Cancer Madison
More informationDepartment of Oncology and Palliative Medicine, Nordland Hospital, 8092 Bodø, Norway 2
The Scientific World Journal Volume 212, Article ID 69323, 5 pages doi:1.11/212/69323 The cientificworldjournal Clinical Study Towards Improved Prognostic Scores Predicting Survival in Patients with Brain
More informationTemporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008
Special Report Temporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008 Matthew B. Schabath, PhD, Zachary J. Thompson, PhD,
More informationStrategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL
New Evidence reports on presentations given at ASH 2009 Strategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL From ASH 2009: Non-Hodgkin
More informationCurrent management of primary central nervous system lymphoma
Review Article Page 1 of 8 Current management of primary central nervous system lymphoma Jon Glass Neurology and Neurological Surgery, Thomas Jefferson University, Philadelphia, PA, USA Correspondence
More informationIntroduction ORIGINAL RESEARCH
Cancer Medicine ORIGINAL RESEARCH Open Access The effect of radiation therapy in the treatment of adult soft tissue sarcomas of the extremities: a long- term community- based cancer center experience Jeffrey
More informationoriginal article introduction original article
Annals of Oncology 18: 665 671, 2007 doi:10.1093/annonc/mdl458 Published online 21 December 2006 Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan/ thiotepa,
More informationThe role of cytoreductive. nephrectomy in elderly patients. with metastatic renal cell. carcinoma in an era of targeted. therapy
The role of cytoreductive nephrectomy in elderly patients with metastatic renal cell carcinoma in an era of targeted therapy Dipesh Uprety, MD Amir Bista, MD Yazhini Vallatharasu, MD Angela Smith, MA David
More informationOsimertinib Activity in Patients With Leptomeningeal Disease From Non-Small Cell Lung Cancer: Updated Results From the BLOOM Study
Osimertinib Activity in Patients With Leptomeningeal Disease From Non-Small Cell Lung Cancer: Updated Results From the BLOOM Study Abstract 9002 Yang JC, Kim DW, Kim SW, Cho BC, Lee JS, Ye X, Yin X, Yang
More informationDiagnosis and Management of Primary Central Nervous System Lymphoma
Diagnosis and Management of Primary Central Nervous System Lymphoma Catherine H. Han, MD 1,2 ; and Tracy T. Batchelor, MD, MPH 1,3 Primary central nervous system lymphoma (PCNSL) is a rare and aggressive
More informationChildhood Cancer Survivor Study Analysis Concept Proposal
Childhood Cancer Survivor Study Analysis Concept Proposal Title: Neurologic and Neurosensory Adverse Sequelae in Long-term Survivors of Childhood Brain Tumors: An Update and Expanded Risk Factor Analysis
More informationPalliative radiotherapy near the end of life for brain metastases from lung cancer: a populationbased
Palliative radiotherapy near the end of life for brain metastases from lung cancer: a populationbased analysis Roel Schlijper Fellow Radiation Oncology BC Cancer, Prince George Disclosures No conflicts
More informationAfter primary tumor treatment, 30% of patients with malignant
ESTS METASTASECTOMY SUPPLEMENT Alberto Oliaro, MD, Pier L. Filosso, MD, Maria C. Bruna, MD, Claudio Mossetti, MD, and Enrico Ruffini, MD Abstract: After primary tumor treatment, 30% of patients with malignant
More informationClinical Study on Prognostic Factors and Nursing of Breast Cancer with Brain Metastases
Clinical Study on Prognostic Factors and Nursing of Breast Cancer with Brain Metastases Ying Zhou 1#, Kefang Zhong 1#, Fang Zhou* 2 ABSTRACT This paper aims to explore the clinical features and prognostic
More informationOriginal Article. Emergency Department Evaluation of Ventricular Shunt Malfunction. Is the Shunt Series Really Necessary? Raymond Pitetti, MD, MPH
Original Article Emergency Department Evaluation of Ventricular Shunt Malfunction Is the Shunt Series Really Necessary? Raymond Pitetti, MD, MPH Objective: The malfunction of a ventricular shunt is one
More informationDr Claire Burney, Lymphoma Clinical Fellow, Bristol Haematology and Oncology Centre, UK
EMBT LWP 2017-R-05 Research Protocol: Outcomes of patients treated with Ibrutinib post autologous stem cell transplant for mantle cell lymphoma. A retrospective analysis of the LWP-EBMT registry. Principle
More informationMetastatic renal cancer (mrcc): Evidence-based treatment
Metastatic renal cancer (mrcc): Evidence-based treatment José M. Ruiz Morales, M.D. Hospital Médica Sur April 18th, 2018 4th ESO-ESMO Latin American Masterclass in Clinical Oncology Disclosures Consulting:
More informationCHILDHOOD CANCER SURVIVAL STUDY CONCEPT PROPOSAL
Version: March 3, 2006 CHILDHOOD CANCER SURVIVAL STUDY CONCEPT PROPOSAL I- Title: Neurocognitive and Psychosocial Correlates of Adaptive Functioning in Survivors of Childhood Leukemia and Lymphoma. II-
More informationSurvival of Pediatric Patients After Relapsed Osteosarcoma: The St. Jude Children s Research Hospital Experience
Survival of Pediatric Patients After Relapsed Osteosarcoma: The St. Jude Children s Research Hospital Experience Sarah E. S. Leary, MD 1,2 ; Amy W. Wozniak, MS 3 ; Catherine A. Billups, MS 2 ; Jianrong
More informationLaboratory data from the 1970s first showed that malignant melanoma
2265 Survival by Radiation Therapy Oncology Group Recursive Partitioning Analysis Class and Treatment Modality in Patients with Brain Metastases from Malignant Melanoma A Retrospective Study Jeffrey C.
More informationEarly-stage mantle cell lymphoma: a retrospective analysis from the International Lymphoma Radiation Oncology Group (ILROG)
Annals of Oncology 28: 2185 219, 217 doi:1.193/annonc/mdx334 Published online 27 June 217 ORIGINAL ARTICLE Early-stage mantle cell lymphoma: a retrospective analysis from the International Lymphoma Radiation
More informationClinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer. Cheol Min Kang 2018/04/05
Abstract No.: ABS-0075 Clinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer 2018/04/05 Cheol Min Kang Department of surgery, University of Ulsan
More informationUniversity of Alberta. Evaluation of Concomitant Temozolomide Treatment in Glioblastoma Multiforme Patients in Two Canadian Tertiary Care Centers
University of Alberta Evaluation of Concomitant Temozolomide Treatment in Glioblastoma Multiforme Patients in Two Canadian Tertiary Care Centers by Ibrahim Alnaami A thesis submitted to the Faculty of
More informationPrognostic Factors for mrcc: Relevance in Clinical Practice
Prognostic Factors for mrcc: Relevance in Clinical Practice Daniel Heng MD MPH FRCPC Chair, GU Tumor Group Tom Baker Cancer Center University of Calgary Prognostic Factors Patient Factors Performance Status
More informationCLINICAL INVESTIGATION of new agents and combination
Interferon-Alfa as a Comparative Treatment for Clinical Trials of New Therapies Against Advanced Renal Cell Carcinoma By Robert J. Motzer, Jennifer Bacik, Barbara A. Murphy, Paul Russo, and Madhu Mazumdar
More informationThe use of surgery in the elderly. for management of metastatic epidural spinal cord compression
The use of surgery in the elderly Bone Tumor Simulators for management of metastatic epidural spinal cord compression Justin E. Bird, M.D. Assistant Professor Orthopaedic Oncology and Spine Surgery Epidemiology
More informationNON-SURGICAL STRATEGY FOR ADULT EPENDYMOMA
NON-SURGICAL STRATEGY FOR ADULT EPENDYMOMA Roberta Rudà Department of Neuro-Oncology University and City of Health and Science Hospital of Turin, Italy EORTC EANO ESMO Conference 2015 Istanbul, March 27-28
More informationOptimal Management of Isolated HER2+ve Brain Metastases
Optimal Management of Isolated HER2+ve Brain Metastases Eliot Sims November 2013 Background Her2+ve patients 15% of all breast cancer Even with adjuvant trastuzumab 10-15% relapse Trastuzumab does not
More information(7) VITAL SIGNS (8) LEVEL OF CONSCIOUSNESS (9) MENTAL STATUS (10) SPEECH (11) VISION (12) FUNDUS (PAPILLEDEMA)
Radiation Therapy Oncology Group Phase II CNS Lymphoma Follow-Up Form RTOG Study No. 1114 Case # Amended Data Yes INSTRUCTIONS: Submit this form as indicated in the protocol. All dates need to be recorded
More informationEfficacy of Treatment for Glioblastoma Multiforme in Elderly Patients (65+): A Retrospective Analysis
Efficacy of Treatment for Glioblastoma Multiforme in Elderly Patients (65+): A Retrospective Analysis Igal Kushnir MD 1 * and Tzahala Tzuk-Shina MD 2 1 Oncology Insitute, Tel Aviv Sourasky Medical Center,
More informationWe have previously reported good clinical results
J Neurosurg 113:48 52, 2010 Gamma Knife surgery as sole treatment for multiple brain metastases: 2-center retrospective review of 1508 cases meeting the inclusion criteria of the JLGK0901 multi-institutional
More informationInduction Chemo-Immunotherapy with the Matrix Regimen in Patients with Newly Di... Advertisement
Page 1 of 5 Induction Chemo-Immunotherapy with the Matrix Regimen in Patients with Newly Diagnosed PCNSL - a Multicenter Retrospective Analysis on Feasibility and Effectiveness in Routine Clinical Practice
More informationOriginal Article. Cancer August 15,
High-Dose Chemotherapy With Thiotepa, Busulfan, and Cyclophosphamide and Autologous Stem Cell Transplantation for Patients With Primary Central Nervous System Lymphoma in First Complete Remission Zachariah
More informationSt. Jude Children's Research Hospital. September 9, 2014 Final Report
The Impact of a Play-Based Procedural Preparation and Support Intervention for Children Undergoing Cranial Radiation for Treatment of a Central Nervous System Tumor St. Jude Children s Research Hospital
More informationBreast Cancer After Treatment of Hodgkin's Disease.
Breast Cancer After Treatment of Hodgkin's Disease. Hancock SL, Tucker MA, Hoppe R Journal of the National Cancer Institute 85(1):25-31, 1993 Introduction The risks of second malignancy are increased in
More informationZurich Open Repository and Archive. Procarbazine and CCNU as initial treatment in gliomatosis cerebri
University of Zurich Zurich Open Repository and Archive Winterthurerstr. 190 CH-8057 Zurich http://www.zora.uzh.ch Year: 2008 Procarbazine and CCNU as initial treatment in gliomatosis cerebri Glas, M;
More informationOutcome of Surgical Resection of Symptomatic Cerebral Lesions in Non-Small Cell Lung Cancer Patients with Multiple Brain Metastases
ORIGIL ARTICLE Brain Tumor Res Treat 2013;1:64-70 / Print ISSN 2288-2405 / Online ISSN 2288-2413 online ML Comm Outcome of Surgical Resection of Symptomatic Cerebral Lesions in Non-Small Cell Lung Cancer
More informationProfessor Mark Bower
BHIVA AUTUMN CONFERENCE 2012 Including CHIVA Parallel Sessions Professor Mark Bower Chelsea and Westminster Hospital, London COMPETING INTEREST OF FINANCIAL VALUE > 1,000: Speaker Name Statement Mark Bower
More informationDr Sneha Shah Tata Memorial Hospital, Mumbai.
Dr Sneha Shah Tata Memorial Hospital, Mumbai. Topics covered Lymphomas including Burkitts Pediatric solid tumors (non CNS) Musculoskeletal Ewings & osteosarcoma. Neuroblastomas Nasopharyngeal carcinomas
More informationMalignant Fibrous Histiocytoma: Database Review Suggests a Favorable Prognosis in the Head and Neck
The Laryngoscope VC 2017 The American Laryngological, Rhinological and Otological Society, Inc. Malignant Fibrous Histiocytoma: Database Review Suggests a Favorable Prognosis in the Head and Neck Robert
More informationRecurrence, new primary and bilateral breast cancer. José Palacios Calvo Servicio de Anatomía Patológica
Recurrence, new primary and bilateral breast cancer José Palacios Calvo Servicio de Anatomía Patológica Ipsilateral Breast Tumor Relapse (IBTR) IBTR can occur in approximately 5 20% of women after breast-conserving
More informationDoes the omission of vincristine in patients with diffuse large B cell lymphoma affect treatment outcome?
Annals of Hematology (2018) 97:2129 2135 https://doi.org/10.1007/s00277-018-3437-z ORIGINAL ARTICLE Does the omission of vincristine in patients with diffuse large B cell lymphoma affect treatment outcome?
More information